Frontlight ResearchEarly access
Active, not recruitingPhase 2
FITMI - First In Treating Male Infertility
Key facts
- Who runs it
- Martin Blomberg Jensen
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 180 people enrolled
- Started
- 1 Jan 2022
- Ended
- 30 Sept 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Denosumab
- Sodium chloride
- Record updated
- 15 November 2024
Who can take part
- Age
- 18 years to 60 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Other criteria
- Inclusion Criterias:
- Infertile men ≥ 18 years and < 60 years of age
- Sperm concentration ≤ 20 million pr. mL
- Serum AMH levels ≥38 pmol/L
- The participants must have appropriate Danish or English language skills and give written informed consent; Exclusion Criterias:
- Chronic diseases, defined as diagnosis where signs, symptoms, and treatment imply an expected long duration and lack of a cure, such as diabetes mellitus, metabolism disorders, osteoporosis, colitis, etc
- Sperm concentration <2 million pr. mL
- Men with current or previous malignancies, or at potential risk of testicular cancer after baseline examination and ultrasound will be excluded
- Men with hypocalcemia at baseline, defined as ionized calcium of < 1,18 mmol/L or albumin corrected calcium < 2,17 mmol/L or total calcium < 2.14 mmol/L
- Serum vitamin D (25OHD) levels < 25 nmol/L
- eGFR < 60 mL/min/1,73 m2
- Insufficient dental status
- Vasectomy
- Semen volume < 0.9 mL
- Hypersensitivity to latex, Denosumab, or to any of the excipients (acetic acid, sodium hydroxide, Sorbitol (E420), Polysorbate 20) will be excluded
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This RCT aims to assess whether treatment with Denosumab can improve semen quality in infertile men selected by serum AMH as a positive predictive biomarker.
The 2 groups in the trial
- DenosumabExisting treatment, for comparison
Subcutaneous injection with 60 mg Denosumab once
- PlaceboPlacebo, for comparison
Subcutaneous injection with NaCl once
Treatment: Sodium chloride
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of a Single-dose Denosumab on Semen Quality in Infertile Men (FITMI): A Randomized Controlled Trial
- Publications
- Effect of denosumab on semen quality in infertile men selected by serum level of antimüllerian hormone: a randomized controlled trial.Fertility and sterility, 2025
- Low-serum antimüllerian hormone is linked with poor semen quality in infertile men screened for participation in a randomized controlled trial.Fertility and sterility, 2024
- Effect of a single-dose denosumab on semen quality in infertile men (the FITMI study): study protocol for a randomized controlled trial.Trials, 2022
- Record updated
- 15 November 2024